Last reviewed · How we verify
ACH-0145228
At a glance
| Generic name | ACH-0145228 |
|---|---|
| Also known as | ALXN2050 |
| Sponsor | Alexion Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (PHASE2)
- Study of ALXN2050 in Participants With Hepatic Impairment (PHASE1)
- Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics (PHASE1)
- Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis (PHASE2)
- Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy (PHASE2)
- Study of ALXN2050 in Participants With Renal Impairment (PHASE1)
- Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants (PHASE1)
- Study of Radiolabeled ALXN2050 in Healthy Adult Males (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACH-0145228 CI brief — competitive landscape report
- ACH-0145228 updates RSS · CI watch RSS
- Alexion Pharmaceuticals, Inc. portfolio CI